Bellwether Market Watch: Teva Specialty Pharmaceuticals and UCB Teaming Up...
TMCnet - The World's Largest Communications and Technology Community
TMC Launches New Sites ::  NGC  |  4GWE  |  Green Tech  |  Satellite  |  IT |  ITEXPO  |  Healthcare  |  Smart Grid  |  M2M  |  Smart Products  |  AstriCon News  |  SATCON News
Share
TMCnews
[January 17, 2008]

Bellwether Market Watch: Teva Specialty Pharmaceuticals and UCB Teaming Up...

(M2 PressWIRE Via Thomson Dialog NewsEdge)
RDATE:17012008

Today Bellwether Report has identified Pharmaceutical Industries Ltd.
(NASDAQ: TEVA), a company that our analysts will be tracking over the
ensuing weeks. They recently came out with a significant corporate
development on Wednesday, January 16, 2008, causing a short term market
correction. For a full report on the below mentioned company, and many
more, feel free to visit www.bellwetherreport.com for a free 90 day no
obligation trial.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among
the top 20 pharmaceutical companies in the world and is the leading
generic pharmaceutical company. Teva Pharmaceutical experienced a minor
uptick last Wednesday, as shares rose to $47.45 on volume of over 6.9
million at the closing bell.

Wednesday, January 16, 2008 Teva Specialty Pharmaceuticals, the U.S.
respiratory therapy unit of Teva Pharmaceutical Industries Ltd. and UCB
(Euronext: UCB) announced an agreement to co-commercialize Teva's U.S.
respiratory medicines. The initial product to be jointly promoted in
the U.S. is Teva's ProAir HFA (albuterol sulfate) Inhalation Aerosol.
ProAir HFA is the number-one branded hydrofluroalkane (HFA) albuterol
sulfate inhaler in the U.S. Additionally, the agreement will provide
UCB future joint promotion opportunities with other products in
development by Teva Specialty Pharmaceuticals. Financial terms of the
agreement were not disclosed.

"Over the last months we have undertaken a rich, strategic review
globally across regions, therapy areas and business units," said
William S. Marth, President and CEO of Teva North America. "The
respiratory therapy area has been identified as a key growth area given
the incidence of asthma, allergic rhinitis, and COPD (chronic
obstructive pulmonary disease). Our collaboration with UCB, a company
known for excellence in the respiratory market, will help us achieve a
stronger presence in this growing therapeutic area."

To view the full unbiased report on Pharmaceutical Industries Ltd.
(NASDAQ: TEVA), feel free to visit our site. This article and many more
are available for review under the Today's Articles Section. No credit
Card Needed!!

The Bellwether Report will continue scanning the markets for true
emerging growth opportunities that will show subscribers optimal entry
points with profitable exit points. If you are interested in receiving
more information on feel free to sign up for a 3 month complimentary
subscription to the #1 online investment resource
www.bellwetherreport.com.

All material herein was prepared by the Bellwetherreport.com,
(Bellwether) based upon information believed to be reliable. The
information contained herein is not guaranteed by Bellwether to be
accurate, and should not be considered to be all-inclusive. The
companies that are discussed in this opinion have not approved the
statements made in this opinion. This opinion contains forward-looking
statements that involve risks and uncertainties. This material is for
informational purposes only and should not be construed as an offer or
solicitation of an offer to buy or sell securities. Bellwether is not a
licensed broker, broker dealer, market maker, investment banker,
investment advisor, analyst or underwriter. Please consult a broker
before purchasing or selling any securities viewed on or mentioned
herein. Bellwether may receive compensation in cash or shares from
independent third parties or from the companies mentioned.

Bellwether's affiliates, officers, directors and employees may also
have bought or may buy the shares discussed in this opinion and may
profit in the event those shares rise in value.

Bellwether will not advise as to when it decides to sell and does not
and will not offer any opinion as to when others should sell; each
investor must make that decision based on his or her judgment of the
market.

This release contains "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans,
results, or strategies and are generally preceded by words such as
"may", "future", "plan" or "planned", "will" or "should", "expected,"
"anticipates", "draft", "eventually" or "projected". You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results
to differ materially from those projected in the forward-looking
statements, including the risks that actual results may differ
materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a companies'
annual report on Form 10-K or 10-KSB and other filings made by such
company with the Securities and Exchange Commission.

You should consider these factors in evaluating the forward-looking
statements included herein, and not place undue reliance on such
statements. The forward-looking statements in this release are made as
of the date hereof and Bellwether undertakes no obligation to update
such statements.

CONTACT: BellwetherReport.com
WWW: http://www.bellwetherreport.com

((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).

Copyright ? 2008 M2 Communications Ltd.

[ Back To TMCnet.com's Homepage ]


Discussions:
Be the first to post a comment on this page!
 
By  
TMCnet
Featured White Papers
Top Stories
Related VoIP News

Subscribe FREE to all of TMC's monthly magazines. Click here now.